在复发性缓解性多发性硬化症中小脑子亚区域性缩:依赖阶段的动态和药理学调制
Xiaohui Zhang1, Jinzhou Feng2, Zhiwei Zhang1
1Department of Radiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Brain research bulletin
|December 9, 2025
概括
多发性硬化症 (MS) 中小脑缩模式因疾病阶段和治疗而异. 特定的小脑区域,特别是XIX和VIIIb叶片,是MS患者治疗反应和认知结果的关键指标.
科学领域:
- 神经科学是一个神经科学.
- 放射学 放射学是一门学科.
- 免疫学 免疫学 免疫学
背景情况:
- 小脑缩是多发性硬化症 (MS) 的重要病理特征.
- 了解不同疾病阶段小脑缩的具体模式以及疾病修饰疗法 (DMT) 的影响至关重要,但尚未得到充分证实.
研究的目的:
- 研究小脑子亚区域体积如何根据复发性复发性多发性硬化 (RRMS) 的阶段变化.
- 评估不同类型的DMT对小脑缩和RRMS患者相关临床结果的影响.
主要方法:
- 分析了181名RRMS患者和99名健康对照.
- 患者按病变活动 (急性活跃,慢性活跃,慢性不活跃) 和DMT类 (未治疗,S1P向,非S1P向) 分类.
- 使用CerebNet深度学习工具量化了小脑亚区域体积;评估了与认知的相关性.
主要成果:
- 在MS各个阶段的脑小叶后部 (Crus II,VIIIa/b,VIIb,X,Crus I,IX) 观察到显著的体积损失.
- 与长期活跃的MS小组相比,急性活跃的MS小组在前叶 (I-IV) 和vermis IX中显示出额外的缩.
- DMT表现出异质的,依据阶段的效应,一些区域在S1P向治疗下显示体积增加,而XI和VIIIb叶片与认知表现相关.
结论:
- 在RRMS中存在明显的,特定阶段的大脑缩模式.
- 德米对大脑后部子区域具有多种不同阶段的作用.
- 第九叶片和第八叶片是关键区域,将治疗效果与认知结果联系起来,表明它们作为MS预后和治疗反应的生物标志物的潜力.
相关概念视频
Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K
Alzheimer's Disease: Treatment
764
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
764
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Parkinson's Disease: Treatment
945
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
945


